Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.59 |
| ▸ | METAP2 | P50579 | 8/20 | 0.53 |
| ▸ | NOS1 | P29475 | 3/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | TDO2 | P48775 | 3/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793841 | 1.00 | IDO1 (0.59) | IDO1METAP2NOS1AXLTDO2 | |
| SCHEMBL17875686 | 0.79 | TDO2 (0.66) | IDO1METAP2NOS1AXLTDO2 | |
| SCHEMBL8404433 | 0.79 | IDO1 (0.63) | IDO1METAP2NOS1AXLTDO2 | |
| SCHEMBL2005425 | 0.77 | METAP2 (0.58) | IDO1METAP2NOS1AXLTDO2 | |
| SCHEMBL30861084 | 0.76 | IDO1 (0.61) | IDO1METAP2TDO2 | |
| SCHEMBL685418 | 0.76 | IDO1 (0.59) | IDO1METAP2AXLTDO2 | |
| SCHEMBL2271744 | 0.76 | IDO1 (0.59) | IDO1METAP2TDO2 | |
| SCHEMBL304051 | 0.76 | IDO1 (0.61) | IDO1METAP2TDO2 | |
| SCHEMBL2003535 | 0.76 | METAP2 (0.53) | IDO1METAP2NOS1AXLTDO2 | |
| SCHEMBL1415060 | 0.76 | NOS1 (0.50) | IDO1METAP2NOS1AXLTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111513-A1 | COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| CN-107556244-B | Fused ring compound, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| EP-2118068-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008107455-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | IDO1 3292/4885METAP2 2289/4885NOS1 1625/4885 |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GPER1, ESR2, ESRRB | IDO1 504/4885METAP2 2445/4885NOS1 2587/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | IDO1 2631/4885METAP2 2877/4885NOS1 4272/4885 |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | IDO1 4606/4885METAP2 4127/4885NOS1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.